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Abstract
Little is known about the long-term survivors of acute 
arsenic intoxication. We present here a clinical case 
report of a man with chronic hepatitis B virus (HBV) 
infection who developed hepatocellular carcinoma four 
years after acute arsenic poisoning. HBsAg was detected 
in serum in 1990 when he voluntarily donated blood. 
In 1991, the patient suffered from severe psychological 
depression that led him to attempt suicide by massive 
ingestion of an arsenic-containing rodenticide. He 
survived with polyneuropathy and paralysis of the lower 
limbs, and has been wheelchair-bound since then. During 
participation in a follow-up study conducted among HBV 
carriers, abdominal ultrasound detected a two-centimeter 
liver mass consistent with hepatocellular carcinoma. The 
tumor was confirmed by computed tomography (CT) 
and magnetic resonance image (MRI). Because of his 
significant comorbidity, the patient received palliative 
treatment with transarterial lipiodol chemoembolization 
(TACE) on three occasions (1996, 1997 and 1999). 
At his most recent visit in May 2005, the patient was 
asymptomatic, liver enzymes were normal and the tumor 
was in remission on ultrasound.
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INTRODUCTION
Arsenic is a recognized human carcinogen established 
by the International Agency for Research on Cancer[1]. 
Chronic arsenic intoxication has been associated with 
skin lesions (such as hyperpigmentation, hyperkeratosis 
and carcinoma) and liver disease (non-cirrhotic portal 
hypertension, hepatocellular carcinoma and angiosarcoma). 
Moreover, chronic arsenic exposure is associated with 
a higher frequency of  diabetes mellitus, ischemic heart 
disease and hypertension[2-4] . Epidemiological studies 
mainly involving cohorts of  chronic arsenic-exposed 
subjects suggest that chronic arsenic intoxication increases 
the risk of  developing liver cancer as compared with non-
exposed populations[5,6] .
Patients who survive the initial effects of  acute 
arsenic exposure may develop peripheral neuropathy and 
encephalopathy[7]. Hepatic injury is uncommon but is 
associated with severe liver disease and high mortality[8]. 
Little is known about the long-term survivors of  acute 
arsenic intoxication. 
We present here a clinical case report of  a Caucasian 
man with chronic hepatitis B virus (HBV) infection who 
developed hepatocellular carcinoma four years after acute 
arsenic poisoning. 
CASE REPORT
The man born in 1947 was obese with no HBV carriers 
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in his family and no previous hepatitis or parenteral drug 
use. He was a heavy smoker and alcohol consumer before 
1987. HBsAg was detected in serum in 1990 when he 
voluntarily donated blood. 
In 1978 he had self-limited cardiac arrhythmia because 
of  stress and in 1991 arrhythmia due to atrial fi brillation 
that reverted with cardioversion. In 1991, the patient 
suffered from severe psychological depression that led 
him to attempt suicide by massive ingestion of  an arsenic-
containing rodenticide. He developed acute renal failure 
and generalized paralysis and was hospitalized for 11 days 
in the intensive care unit, requiring assisted ventilation 
and chelation therapy with dimercaprol. He survived 
with polyneuropathy and paralysis of  the lower limbs, 
and has been wheelchair-bound since then. In 1994 and 
1995 he suffered from several transient ischemic attacks 
that were managed with chronic decoagulation therapy. 
In 2000 diabetes was diagnosed. He also required long-
term treatment for sleep apnea-hypoapnea syndrome with 
automatic continuous positive airway pressure.
In November 1995 he was invited to participate in 
a follow-up study conducted in HBV carriers[9]. The 
viral serology results were negative for HBsAg, anti-
HBs, HBeAg, IgM-anti-HBc, and positive for anti-HBe, 
IgG-anti-HBc. Serum HBV-DNA was negative by PCR 
technique, while anti-HDV, anti-HCV and anti-HIV were 
all negative. ALT was 1.36 μKat/mL (normal <0.5 μKat/
mL), AST and alpha-fetoprotein were normal. Abdominal 
ultrasound detected a pattern suggestive of  chronic liver 
disease and a liver mass two centimeters in diameter 
consistent with hepatocellular carcinoma. The tumor was 
confirmed by computed tomography (CT) scanning and 
magnetic resonance imaging. Because of  his comorbidity, 
the patient was not considered eligible for liver transplant 
or hepatectomy. Palliative treatment with transarterial 
lipiodol chemoembolization (TACE) was performed on 
three occasions (1996, 1997 and 1999) (Figure 1) with 
clinical, analytical and imaging follow-up studies (Figure 
2). At his last visit in May 2005, he was asymptomatic, liver 
enzymes were normal and the tumor was in remission on 
ultrasound imaging. 
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DISCUSSION
To the best of  our knowledge, this patient is the first 
known case of  liver tumor developed after acute arsenic 
exposure. Standard chelat ion treatment for acute 
intoxication could not remove arsenic from intracellular 
sites because of  its lipophobic nature, suggesting that this 
treatment cannot protect cells from long-term clinical 
consequences[10]. As has been described, the presence of  
intracellular arsenic may be related to the development of  
diabetes, arterial hypertension, ischemic arterial disease 
and liver cancer in such patients. It should also be taken 
into consideration that intraindividual variability in arsenic 
methylation can increase susceptibility to arsenic-induced 
cancer[11]. 
Given the fact that the patient was obese and had 
occult HBV infection (his anti-HBc and anti-HBe positive 
status could indicate integration of  the virus in the host 
genome) prior to arsenic intake, we are not sure that some 
hepatic injury is not due to these risk factors[12,13] . The 
presence of  these risk factors may enhance the hepatic 
lesion and the development of  liver cancer. 
Angiosarcoma is the type of  liver tumor most often 
related with chronic arsenic exposure[5]. In our case, 
histological confirmation of  the liver tumor could not be 
performed due to the anticoagulant treatment (Sintrom®). 
However, the features of  the tumor on CT and TACE 
are consistent with hepatocellular carcinoma, particularly 
when the tumor characteristics are considered after 
lipiodol uptake during and after TACE[14].  Even though 
the most effective therapy for hepatocellular carcinoma is 
liver transplantation or partial hepatectomy[15], our patient 
remains asymptomatic after nine years of  TACE treatment. 
This fact is consistent with the increasing survival rates of  
patients receiving this palliative treatment[16].
In conclusion, this is the first patient with occult 
HBV infection who developed hepatocellular carcinoma 
after acute arsenic exposure, and his tumor remitted after 
palliative treatment with TACE. The clinical implication 
of  our observation is that periodical liver studies should 
be undertaken in patients who survive after acute arsenic 
exposure.
www.wjgnet.com
Figure 1 Non-contrast CT one month after arterial chemoembolization with 
iodized oil (Lipiodol) and doxorubicine emulsion. CT shows a 2-cm nodule with 
dense Lipiodol enhancement in segment VI (arrow), consistent with hepatocellular 
carcinoma.
Figure 2 Follow-up contrast-enhanced CT five years later from 1995 shows a 
small hypervascular lesion (arrow) in segment VI consistent with residual tumor. 
Tumoral Lipiodol retention was absent and the size of the lesion was signifi cantly 
decreased.
10 
cm
REFERENCES
1 International Agency for Research on Cancer. Some drinking-
water disinfectants and contaminants, including arsenic. IARC 
Monogr Eval Carcinog Risks Hum 2004; 84: 1-477
2 Chen CJ, Wang CJ. Ecological correlation between arsenic 
level in well water and age-adjusted mortality from malignant 
neoplasms. Cancer Res 1990; 50: 5470-5474 
3 Centeno JA, Mullick FG, Martinez L, Page NP, Gibb H, Long-
fellow D, Thompson C, Ladich ER. Pathology related to chron-
ic arsenic exposure. Environ Health Perspect 2002; 110 Suppl 5: 
883-886 
4 Nevens F, Fevery J, Van Steenbergen W, Sciot R, Desmet V, 
De Groote J. Arsenic and non-cirrhotic portal hypertension. A 
report of eight cases. J Hepatol 1990; 11: 80-85 
5 Regelson W, Kim U, Ospina J, Holland JF. Hemangioendo-
thelial sarcoma of liver from chronic arsenic intoxication by 
Fowler’s solution. Cancer 1968; 21: 514-522 
6 Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms 
among residents of a blackfoot disease-endemic area in Tai-
wan: high-arsenic artesian well water and cancers. Cancer Res 
1985; 45: 5895-5899
7 Goebel HH, Schmidt PF, Bohl J, Tettenborn B, Kramer G, 
Gutmann L. Polyneuropathy due to acute arsenic intoxication: 
biopsy studies. J Neuropathol Exp Neurol 1990; 49: 137-149 
8 Vantroyen B, Heilier JF, Meulemans A, Michels A, Buchet 
JP, Vanderschueren S, Haufroid V, Sabbe M. Survival after a 
lethal dose of arsenic trioxide. J Toxicol Clin Toxicol 2004; 42: 
889-895 
9 Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepato-
cellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v
10 Kalia K, Flora SJ. Strategies for safe and effective therapeu-
tic measures for chronic arsenic and lead poisoning. J Occup 
Health 2005; 47: 1-21 
11 Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. Intra-
individual variability in arsenic methylation in a U.S. popula-
tion. Cancer Epidemiol Biomarkers Prev 2005; 14: 919-24 
12 Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, 
Crax A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, 
Raimondo G. Hepatitis B virus maintains its pro-oncogenic 
properties in the case of occult HBV infection. Gastroenterology 
2004; 126: 102-110
13 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-
weight, obesity, and mortality from cancer in a prospectively 
studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
14 Valls C, Cos M, Figueras J, Andia E, Ramos E, Sanchez A, 
Serrano T, Torras J. Pretransplantation diagnosis and stag-
ing of hepatocellular carcinoma in patients with cirrhosis: 
value of dual-phase helical CT. AJR Am J Roentgenol 2004; 182: 
1011-1017
15 Figueras J, Ramos E, Ibanez L, Valls C, Serrano T, Rafecas A, 
Casanovas T, Fabregat J, Xiol X, Torras J, Baliellas C, Jaurrieta E, 
Casais L. Surgical treatment of hepatocellular carcinoma. Long 
term results Med Clin (Barc) 2002; 118: 410-414
16 Llovet JM, Bruix J. Systematic review of randomized trials for 
unresectable hepatocellular carcinoma: Chemoembolization 
improves survival. Hepatology 2003; 37: 429-42 
S- Editor  Guo SY    L- Editor  Wang XL    E- Editor  Bai SH
1974       ISSN 1007-9327      CN 14-1219/ R     World J Gastroenterol      March 28, 2006    Volume 12       Number 12
www.wjgnet.com
